Back to Search
Start Over
Sugammadex efficacy for reversal of rocuronium- and vecuronium-induced neuromuscular blockade: A pooled analysis of 26 studies.
- Source :
-
Journal of Clinical Anesthesia . Sep2017, Vol. 41, p84-91. 8p. - Publication Year :
- 2017
-
Abstract
- <bold>Study Objective: </bold>To summarize and compare efficacy of sugammadex with neostigmine or placebo for reversal of rocuronium- or vecuronium-induced neuromuscular blockade (NMB), and to demonstrate consistency of sugammadex results across various patient populations.<bold>Design: </bold>Pooled analysis on data from 26 multicenter, randomized, Phase II and III studies.<bold>Setting: </bold>Operating room.<bold>Patients: </bold>1855 adults undergoing surgery under general anesthesia and receiving rocuronium or vecuronium for NMB.<bold>Interventions: </bold>Sugammadex (2.0mg/kg at second twitch reappearance [T2; moderate NMB], 4.0mg/kg at 1-2 post-tetanic counts [PTC; deep NMB] or 16.0mg/kg at 3min after rocuronium 1.2mg/kg), neostigmine or placebo.<bold>Measurements: </bold>Time to recovery of the train-of-four (TOF) ratio to 0.9.<bold>Main Results: </bold>Geometric mean (95% CI) times to recovery to TOF ratio of 0.9 were 1.9 (1.8-2.0) min following sugammadex 2.0mg/kg and 10.6 (9.8-11.6) min following neostigmine administration at T2 after rocuronium, and 2.9 (2.5-3.4) min and 17.4 (13.4-22.6) min, respectively, after vecuronium. Recovery times were 2.2 (2.1-2.3) min following sugammadex 4.0mg/kg and 19.0 (14.8-24.6) min following neostigmine administered at a target of 1-2 PTC after rocuronium, and 3.8 (3.0-5.0) min and 67.6 (56.3-81.2) min after vecuronium. Sugammadex administered 3min after rocuronium 1.2mg/kg resulted in rapid recovery (1.7 [1.5-2.0] min). Modest increases in mean recovery time were associated with vecuronium use (+1.6min [78%; (61%-98%)] versus rocuronium), mild-to-moderate renal impairment (+0.4min [20%; (9%-32%)] versus normal renal function) and geographic location (+1.0min [38%; (25%-52%)] in subjects in USA/Canada versus Europe/Japan).<bold>Conclusions: </bold>Sugammadex administered at recommended doses provides rapid and predictable reversal of rocuronium and vecuronium-induced moderate and deep NMB, and effective reversal 3min after rocuronium 1.2mg/kg. Robust recovery was seen across various patient factors, providing further confirmation of labeled dose recommendations. [ABSTRACT FROM AUTHOR]
- Subjects :
- *ROCURONIUM bromide
*VECURONIUM bromide
*SUGAMMADEX
*KIDNEY abnormalities
*NEUROMUSCULAR blocking agents
*STEROID drugs
*CURARE-like agents
*ANESTHESIA
*CHOLINESTERASE inhibitors
*CLINICAL trials
*COMPARATIVE studies
*DOSE-effect relationship in pharmacology
*GLUCANS
*RESEARCH methodology
*MEDICAL cooperation
*PARASYMPATHOMIMETIC agents
*PLACEBOS
*RESEARCH
*TIME
*EVALUATION research
*TREATMENT effectiveness
*GENERAL anesthesia
*THERAPEUTICS
Subjects
Details
- Language :
- English
- ISSN :
- 09528180
- Volume :
- 41
- Database :
- Academic Search Index
- Journal :
- Journal of Clinical Anesthesia
- Publication Type :
- Academic Journal
- Accession number :
- 124578310
- Full Text :
- https://doi.org/10.1016/j.jclinane.2017.06.006